MedTrace Logo

Tafenoquine and ACTs (TADORE- Plus)

NCT07060794 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 507

Last updated 2026-03-18

No results posted yet for this study

Summary

A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).

Conditions

  • Vivax Malaria

Interventions

DRUG

Tafenoquine plus DHA-Piperaquine

Tafenoquine plus DHA-piperaquine

DRUG

Tafenoquine plus Artesunate-pyronaridine

Tafenoquine plus Artesunate-pyronaridine

Sponsors & Collaborators

  • Menzies School of Health Research

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2028-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07060794 on ClinicalTrials.gov